Sanofi generates €9.7 billion in sales in Q1 2022

Pharmaceutical company confirmes outlook for 2022

Sanofi Headquarters

Pharmaceutical company Sanofi has presented strong results for the first quarter of 2022. Sales grew by around 13 percent to 9.7 billion euros. Exchange rate fluctuations had a positive impact, mainly due to the dollar. Overall, the French company benefited from good business with its neurodermatitis and asthma drug from January to March 2022, but business with over-the-counter medicines showed double-digit growth. Operating profit adjusted for special items improved 16 percent to 3.07 billion euros. Profit rose by 20 percent to around two billion euros.

Sanofi Chief Executive Officer, Paul Hudson, commented: “We are off to a strong start to 2022 propelled by the continued outstanding performance of Dupixent, double-digit growth of our CHC business and improved margins in the first quarter. In R&D, we increased our investments to fuel our rapidly advancing pipeline which was further enhanced through BD collaborations such as Seagen, IGM, Exscientia and Blackstone during the period. As highlighted at our investor event in March, we remain focused on our path to industry leadership in Immunology. Based on the strong first quarter, we are on track to deliver on our 2022 financial guidance, despite the challenging business environment.“

Development of the Sanofi business units

In the first quarter of 2022, sales in the Pharmaceuticals business unit climbed by 7.5 percent to 7.33 billion euros, mainly thanks to the Specialty Care portfolio with an increase of 17.8 percent. The Pharmaceuticals business unit comprises the two segments "Specialty Care" with the therapeutic areas neurodermatitis and asthma, oncology, neurology and immunology, rare diseases and rare blood disorders, as well as "General Medicines". In the first quarter, the operating result of this business unit rose by 12.6 percent to 2.83 billion euros. Sales of General Medicines decreased 0.7 percent to 3.76 billion euros in the first quarter and remained stable excluding portfolio adjustments. Sales in the Vaccines business unit increased by 6.8 percent to 1.02 billion euros in the first quarter. The business unit benefited from double-digit growth in sales of polio/pertussis/Hib vaccines and a partial recovery in travel vaccines. Sales of non-prescription medicines in the third Consumer Healthcare business unit rose 17 percent to 1.33 billion euros in the first quarter, driven by growth in Europe and the Rest of the World region. This development was driven primarily by strong demand for cough and cold products, as well as by the development of pain medicines and agents to promote digestion.